ArticleInternational journal of clinical oncology2025

Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors.

Masaya Takahashi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.